Cencora, Inc. (NYSE:COR) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 15.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,569 shares of the company’s stock after acquiring an additional 207 shares during the period. Farther Finance Advisors LLC’s holdings in Cencora were worth $351,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Fisher Asset Management LLC purchased a new position in shares of Cencora in the fourth quarter valued at $244,000. Trust Co. of Vermont bought a new position in Cencora during the 4th quarter valued at $62,000. Wahed Invest LLC bought a new position in Cencora during the 4th quarter valued at $567,000. Vanguard Group Inc. bought a new position in shares of Cencora in the 4th quarter worth about $4,212,508,000. Finally, Hennessy Advisors Inc. bought a new position in shares of Cencora in the 4th quarter worth about $3,307,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders sold a total of 4,450,399 shares of company stock worth $1,070,392,799 in the last quarter. Insiders own 15.80% of the company’s stock.

Cencora Stock Performance

COR opened at $243.36 on Thursday. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company has a market capitalization of $48.54 billion, a PE ratio of 26.63, a price-to-earnings-growth ratio of 1.57 and a beta of 0.45. The business has a fifty day simple moving average of $232.08 and a 200 day simple moving average of $233.16. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $247.66.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the business posted $2.92 earnings per share. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis. Research analysts expect that Cencora, Inc. will post 13.61 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.84%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on COR shares. Robert W. Baird increased their price objective on shares of Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Leerink Partners reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Wells Fargo & Company increased their price objective on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Finally, StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $258.63.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.